IRON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Disc Medicine Inc (IRON) is not a strong buy for a beginner, long-term investor at this moment. The stock lacks immediate positive catalysts, has ongoing legal investigations, insider selling activity, and financial performance that remains in negative territory. While analysts maintain generally positive ratings, the recent FDA rejection and subsequent uncertainty around its key drug, bitopertin, weigh heavily on the stock. The technical indicators and trading signals do not suggest a strong entry point either.
The MACD is above 0 and positively contracting, indicating mild bullish momentum. RSI is neutral at 46.176, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot point of 69.126, with key support at 66.475 and resistance at 71.777. Overall, the technical indicators do not strongly favor a buy.
Analysts maintain generally positive ratings with price targets significantly above the current price. The ongoing Phase 3 APOLLO trial for bitopertin could provide clarity in mid-to-late April, potentially acting as a positive catalyst.
The FDA's rejection of bitopertin's NDA has created uncertainty. Legal investigations, including potential securities fraud claims, could impact investor sentiment. Insider selling by the CMO further raises concerns. Technical indicators and trading signals do not support a strong buy.
In Q4 2025, revenue remained at 0 with no growth. Net income improved YoY but remains negative at -$60.53M. EPS improved to -1.61, but the company is still unprofitable. Gross margin is 0, reflecting no revenue generation.
Analysts generally maintain positive ratings with price targets ranging from $75 to $125. However, recent downgrades reflect concerns about clinical risks and delays in bitopertin's approval. Analysts remain optimistic about the Phase 3 APOLLO trial and long-term potential.
